Lexaria Bioscience Corp. (LEXX)
| Bid | 1.15 |
| Market Cap | 23.19M |
| Revenue (ttm) | 525.92K |
| Net Income (ttm) | -9.38M |
| EPS (ttm) | -0.61 |
| PE Ratio (ttm) | -1.95 |
| Forward PE | -2.57 |
| Analyst | Buy |
| Ask | 1.24 |
| Volume | 125,402 |
| Avg. Volume (20D) | 106,653 |
| Open | 1.21 |
| Previous Close | 1.23 |
| Day's Range | 1.19 - 1.23 |
| 52-Week Range | 1.14 - 4.44 |
| Beta | 0.85 |
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time ...
Analyst Forecast
According to 1 analyst ratings, the average rating for LEXX stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 488.09% from the latest price.
Stock Forecasts
2 months ago · thenewswire.com
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm5 th study arm in 12-week Phase 1b Study receives lead clinical site approval Kelowna, British Columbia – February 24, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Comp...
2 months ago · accessnewswire.com
Lexaria's Strategic Business Pursuit of DehydraTECH-LiraglutidePursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global...